Concurrent chemoradiotherapy in non-small cell lung cancer

Area of Science:

• Oncology
• Radiotherapy
• Medical Oncology

Background:

• Concurrent chemotherapy and radiotherapy in non-small cell lung cancer (NSCLC) aims to enhance radiotherapy effectiveness and reduce metastatic disease.
• This is an updated review incorporating new trials and mature data since its 2004 publication.

Purpose of the Study:

• To evaluate the effectiveness of concurrent chemoradiotherapy versus radiotherapy alone for NSCLC regarding overall survival, tumor control, and treatment toxicity.
• To compare the efficacy of concurrent chemoradiotherapy against sequential chemoradiotherapy.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Searches conducted in CENTRAL, MEDLINE, and EMBASE databases up to October 2009.
• Inclusion of randomized trials comparing concurrent chemoradiotherapy with radiotherapy alone, or concurrent versus sequential chemoradiotherapy in stage I-III NSCLC patients.

Main Results:

• Concurrent chemoradiotherapy significantly reduced the overall risk of death (HR 0.71) and improved progression-free survival compared to radiotherapy alone.
• Concurrent treatment led to increased incidence of acute esophagitis and neutropenia.
• Concurrent chemoradiotherapy showed a significant overall survival benefit (HR 0.74) over sequential treatment, representing a 10% absolute survival benefit at 2 years.
• Higher rates of severe esophagitis were observed with concurrent treatment.

Conclusions:

• Concurrent chemoradiation demonstrates a clear benefit over radiotherapy alone or sequential chemoradiotherapy for NSCLC.
• Patient selection is crucial due to the increased toxicity associated with concurrent treatment.
• Further research is needed to determine if modern radiotherapy techniques could achieve similar benefits with potentially reduced toxicity.